Learn more In the latest trading session, Amgen (AMGN) closed at $344.55, marking a -1.17% move from the previous day. The stock fell short of the S&P 500, which registered a gain of 0.8% for the day.

Amgen recently announced that David M. Reese, M.D., its long-serving executive vice president and Chief Technology Officer, ...

Biotech giant Amgen on April 22 announced the retirement of David Reese, executive vice president and chief technology officer, who has been with the Thousand Oaks-based company for 21 years. Reese, ...

In this article, we will list the 5 Best Stem Cell Therapy Stocks to Buy. If you wish to see the methodology behind the ...

Amgen announced 52-week results from a phase 2 trial with its weight-management candidate, MariTide. The results Amgen posted don't appear very competitive with Eli Lilly's weight management drug, ...

Amgen AMGN is one of the several drug makers racing to develop the next blockbuster weight loss drug and take a share of the booming weight loss drug market. The obesity market is expected to expand ...

Delve into the pipeline strategy of major biotech Amgen, which is increasingly diversifying its growth engines.

Amgen AMGN delivered yet another strong quarterly performance. Its second-quarter 2025 earnings and sales beat estimates. The company has been recording consistently strong top-line performance. Amgen ...

The drug, MariTide, also helped patients with obesity and Type 2 diabetes lose up to 17% of their weight after a year. The company said it did not observe a plateau in either group of patients, which ...

Amgen's MariTide shows up to 20% weight loss in Phase II, leaving room for improvement beyond 52 weeks, as weight loss did not plateau. GI side effects are a concern, but Amgen plans to address them ...

Amgen's MariTide aims for quicker weight loss, fewer doses than GLP-1 drugs Analysts expect MariTide to show at least 20% weight loss Concerns over side effects, including nausea and bone density ...

Amgen Inc. (NASDAQ:AMGN) and Kyowa Kirin released preliminary topline results from the ASCEND study evaluating rocatinlimab in adults and adolescents with moderate to severe atopic dermatitis (AD) on ...